This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Lowering your “bad” cholesterol might be doing more than just protecting your heart, it could also be safeguarding your brain ...

Body weight also affects cholesterol levels. “Obese or overweight individuals are at a higher risk of producing LDL ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...